ELEKTA INSTRUMENT AB K061540

Dokumentnamn/Name of document

Special 510(k)

Utfärdare/Issuer Louise Lindblad	Ref nr/Dok nr/Ref no/Doc no	Utgåva /Edition
Avser/Regarding		Directory
Leksell GammaPlan®		

Section 4 - 510(k) Summary

As Required by 21 CFR 807.87(k)510 (k) Summary

Subscribers Name & Address 1.

Elekta Instrument AB Kungstensgatan 18, P:O Box 7593 SE-103 93 Stockholm, Sweden Tel: (011) 46 8 587 254 00

Fax: (011) 46 8 587 255 00

Contact Person for this submission: Ms Louise Lindblad

Official Correspondent: Mr Peter Löwendahl

Trade Name 2.

Leksell GammaPlan®

Device Classification 3.

Common Name	Product Code	Class	Regulation Number
Radionuclide radiation therapy system	IWB	II	892.5750

Regulatory History (Unmodified Predicate Device) 4.

Devices	510(k) #
GammaPlan®	K051022

Other relevant submissions 5.

Devices	510(k) #
Leksell GammaPlan®	K973441
Ecksell Gallillat latt	

ELEKTA INSTRUMENT AB

K061540

Dokumentnamn/Name of document Special 510(k)

Utfärdare/Issuer	Ref nr/Dok nr/Ref no/Doc no	Utgâva /Edition	
Louise Lindblad	-	1	
Avser/Regarding		Directory	
Leksell GammaPlan®			

6. Device Description (for detailed description see Section "Device Description")
Leksell GammaPlan® is a computer-based dose planning system specifically designed for use with the Leksell Gamma Knife®. Leksell Gamma Plan® is intended to be used for planning the dosimetry of treatments, in stereotactic radiosurgery and stereotactic radiotherapy.

7. Intended Use

Leksell GammaPlan® is a computer-based dose planning system specifically designed for use with Leksell Gamma Knife®.

8 Substantial Equivalence
The functionality for Leksell GammaPlan® is equivalent to its predicate devices
GammaPlan® (K051022) and Leksell GammaPlan® (K973441) in safety and effectiveness.
The fundamental technical characteristics are similar to those of the predicate devices.

DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850

JUL - 5 2006

Ms. Louise Lindblad Elekta Instrument AB Kungstensgatan18 P.O. Box 7593 Stockholm SWEDEN SE-103 93

Re: K061540

Trade/Device Name: Leksell GammaPlan® Regulation Number: 21 CFR §892.5750

Regulation Name: Radionuclide radiation therapy system

Regulatory Class: II Product Code: IWB Dated: May 30, 2006 Received: June 5, 2006

Dear Ms. Lindblad:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.



Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxx	(Gastroenterology/Renal/Urology	240-276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 894.xxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mancy Choadon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

ELEKTA INSTRUMENT AB

Dokumentnamn/Name of document

Special 510(k)

Utfärdare/Issuer	Ref nr/Dok nr/Ref no/Doc no	Utgåva /Edition
Louise Lindblad	•	1
Avser/Regarding		Directory
Leksell GammaPlan®		

Leksell GammaPian®			
Section 7- Indications for Use Statement			
510(k) Number	To be defined	K061540	
Device Name	Leksell GammaP	'lan [®]	
Indications for Use		lan [®] is a computer-b gned for use with Lek	ased dose planning system sell Gamma Knife [®] .
Prescription Use X (Part 21 CFR 801 Subpa		AND/OR	Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE	E BELOW THIS LIN	ne - Continue on A	another page if necessary)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off) Division of Reproductive, Abdominel, and Radiological Devices 510(k) Number _____